1Booster influenza vaccination does not improve immune response in adult inflammatory bowel disease patients treated with immunosuppressives: A randomized controlled trialJournal of Gastroenterology  Clinical Article
2Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: A five-arm phase 2 studyThe Lancet Oncology  Clinical Article
3NEOSCOPE: A randomised Phase II study of induction chemotherapy followed by either oxaliplatin/capecitabine or paclitaxel/carboplatin based chemoradiation as pre-operative regimen for resectable oesophageal adenocarcinomaBMC Cancer  Full Text  Clinical Article
4Safety and efficacy of endoscopic spray cryotherapy for Barrett's dysplasia: results of the National Cryospray RegistryDiseases of the Esophagus  Clinical Article
5The prevalence of gastro-esophageal reflux disease and esophageal dysmotility in Chinese patients with idiopathic pulmonary fibrosisBMC Gastroenterology  Full Text  Clinical Article
6Nerve growth factor neutralization suppresses β-cell proliferation through activin A and betacellulinPancreas  Clinical Article
7Phase II study of mFOLFOX3 as second-line treatment after gemcitabine failure in patients with unresectable/metastatic biliary tract cancerCancer Chemotherapy and Pharmacology  Clinical Article
8Effectiveness and safety of immunomodulators with anti-TNF therapy in Crohn's diseaseClinical Gastroenterology and Hepatology  Clinical Article
9Helicobacter pylori induces serine phosphorylation of EGFR via novel TAK1-p38 activation pathway in an HB–EGF-independent manner.Helicobacter  Clinical Article
10Gender differences in fecal immunochemical test performance for early detection of colorectal neoplasiaClinical Gastroenterology and Hepatology  Clinical Article
1IU researchers: Pancreatic cancer patients with particular gene signature may benefit from personalized treatmentIndiana University School of Medicine News
2Widely used food additive promotes colitis, obesity and metabolic syndrome, research showsGeorgia State University News
3How the landscape of the pancreatic cancer genome is coming into viewGarvan Institute of Medical Research News
4Bariatric surgery affects risk of pregnancy complicationsKarolinska Institutet
5Plant chemicals may prevent liver damage caused by fat accumulated during menopauseUniversity of Georgia Research News
6NewYork-Presbyterian Hospital/Weill Cornell Medical Center develops new procedure to alleviate common side effects for gastric bypass patientsNewYork-Presbyterian
7Yale researchers reverse type 2 diabetes and fatty liver disease in ratsYale School of Medicine News
8Gut microbes targeted for diagnosis, treatment of childhood undernutritionWashington University School of Medicine in St. Louis News
9Nearly half a million Americans suffered from Clostridium difficile infections in a single yearCDC
10Stellate cells in the liver control regeneration and fibrosisGerman Cancer Research Center News

Show Me:

SIRT3 expression improves prognosis in gastric cancer

As reported in the World Journal of Surgery, SIRT3 expression improves the prognosis in patients with gastric cancer (n=221). Specifically, the 5-year OS was 51.2% and 39.1% in patients who do and do not express SIRT3, respectively. The 5-year DFS was 49.6% and 38.0% in patients who do and do not express SIRT3, respectively. Patients who do not express SIRT3 are characterized by increased poor cellular differentiation, increased diffuse-type Lauren’s histology, and increases scirrhous-type stromal reactions, suggesting the SIRT3 functions as a tumor suppressor.

Risk factors for CHC-related death identified

As reported in the World Journal of Gastroenterology, the following risk factors for chronic hepatitis C (CHC)-related deaths have been identified (n=8250 CHC patients; n=144 CHC-related deaths): α-IFN therapy (AOR=0.53); liver cirrhosis (AOR=2.89); hepatocellular carcinoma versus CHC (AOR=8.82); hypertension (AOR=1.76); alcohol consumption (AOR=1.73); and HBsAg positivity (AOR=22.28).

Risk factors for intra-abdominal abscesses in Crohn’s disease

As reported in Digestion, uncontrolled CRP at week 14 of therapy with infliximab (OR=1.36) and early loss of response to infliximab (OR=5.36) are independent risk factors for intra-abdominal abscesses in patients with Crohn’s disease.

Are YOU the Smartest Doc in America?

The Smartest Doc from MDLinx keeps you current with a competitive edge, pitting colleagues against one other for the title of The Smartest Doc in America.

Take the Challenge

Clinical Pearls

Clinical Pearl from Smartest DocDie laparoskopische Fundoplicatio ist eine effektive Therapie für GERD, die Erfolgsrate beim 20-Jahres-Followup betrug 80 %.

Clinical Pearl from Smartest DocLeptin and insulin are associated with Barrett's esophagus.

Clinical Pearl from Smartest DocBoys and girls may benefit from different subtype-specific treatment approaches for IBS.

The Top Read Articles of 2014 are Now Available

Scouring thousands of peer-reviewed journals and popular press, Our Editors just released the Top Read Articles of the Year. See the Top Read List